Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda, Marta Domènech, Ainhoa Hernández, et al.
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 71-86
Open Access | Times Cited: 20

Showing 20 citing articles:

Glioblastoma Therapy: Past, Present and Future
Elena Obrador, Paz Moreno-Murciano, María Oriol‐Caballo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2529-2529
Open Access | Times Cited: 63
Clinical Theranostics in Recurrent Gliomas: A Review
Austin R. Hoggarth, Sankar Muthukumar, Steven Thomas, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1715-1715
Open Access | Times Cited: 10
Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib
Ana M Muñoz‐Mármol, Bárbara Meléndez, Ainhoa Hernández, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 375-375
Open Access | Times Cited: 1
Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme
Tanvir Ahmed, Kazi Tasnuva Alam
AAPS PharmSciTech (2025) Vol. 26, Iss. 3
Closed Access | Times Cited: 1
Development of a Targeted SN-38-Conjugate for the Treatment of Glioblastoma
Perpetue Bataille Backer, Tayo Alex Adekiya, Yushin Kim, et al.
ACS Omega (2024) Vol. 9, Iss. 2, pp. 2615-2628
Open Access | Times Cited: 7
CD133 significance in glioblastoma development: in silico and in vitro study
Mahdi Abdoli Shadbad, Fatemeh Nejadi Orang, Behzad Baradaran
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 6
A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma
Nathaniel Rolfe, Nicholas B. Dadario, Peter Canoll, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 973-973
Open Access | Times Cited: 4
Farnesol Inhibits Cell Viability and Activates Apoptosis in Glioma C6 Cells via Downregulating Phosphoinositide 3-kinase (PI3K)/Protein Kinase B (AKT)/Mammalian Target of Rapamycin (mTOR) Pathway
Chao Gao, Shu-Jem Su, Qi Guan, et al.
Pharmacognosy Magazine (2025)
Closed Access
The Prognostic Value of the Systemic Immune-Inflammation Index in Glioblastoma Patients and the Establishment of a Nomogram
Hao Xu, Lihao Jiang, Shengnan Yu, et al.
Current Medical Science (2025)
Closed Access
Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells
Ermira Mulliqi, Said Khelwatty, Anna Morgan, et al.
World Journal of Oncology (2024) Vol. 15, Iss. 3, pp. 492-505
Open Access | Times Cited: 3
Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment
Shilpi Singh, Debashis Barik, Karl Lawrie, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14960-14960
Open Access | Times Cited: 8
Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts
Laxmi Dhungel, Cayla Harris, Lauren Romine, et al.
Bioengineering (2023) Vol. 10, Iss. 6, pp. 718-718
Open Access | Times Cited: 4
Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans
Łukasz Uram, Natalia Pieńkowska, Maria Misiorek, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3226-3226
Open Access | Times Cited: 1
Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus
Praveen Bhoopathi, Padmanabhan Mannangatti, Anjan K. Pradhan, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 8
Closed Access | Times Cited: 1
Design of Experiments to Tailor the Potential of BSA-Coated Peptide Nanocomplexes for Temozolomide/p53 Gene Co-Delivery
Inês S. Afonso, Ana R. Neves, Dalinda Eusébio, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1389-1389
Open Access | Times Cited: 1
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment
Suming Wang, Victor Zota, Melanie Vincent, et al.
Research Square (Research Square) (2024)
Open Access
Epigenetic Characteristics in Primary and Recurrent Glioblastoma—Influence on the Clinical Course
Alexander Quiring, Hannah Spielmann, Fritz Teping, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2078-2078
Open Access
Evaluating treatment outcome of Glioblastoma with Stupp’s regimen: an experienced in single Institute
Dang Nguyen Van, Nhung Nguyen Thi Thu, Phan Nguyen Huy, et al.
Research Square (Research Square) (2024)
Open Access
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment
Suming Wang, Victor Zota, Melanie Y. Vincent, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Revolutionizing treatment for recurrent glioblastoma with intraventricular CARv3-TEAM-E T cells
Ayush Anand, Nathnael Abera Woldehana, Prakasini Satapathy, et al.
International Journal of Surgery Open (2024) Vol. 62, Iss. 3, pp. 284-285
Open Access
Page 1

Scroll to top